Search research articles
Contact Us
Filters
Showing results (1-10 of 115) with videos related to
Page
of 12
Sort By:
Journal of Clinical Hypertension (Greenwich, Conn.)
|
July 30, 2013
What does ALLHAT tell us about dyslipidemia from the hypertension specialist perspective?
Michael J Bloch
Journal of the American College of Cardiology
|
July 18, 2020
Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?
Michael J Bloch
Journal of the American Society of Hypertension : JASH
|
June 10, 2016
Spironolactone is the Most Effective "add-on" Medication For Resistant Hypertension
Michael J Bloch
Journal of the American Society of Hypertension : JASH
|
September 24, 2016
Worldwide prevalence of hypertension exceeds 1.3 billion
Michael J Bloch
Journal of the American Society of Hypertension : JASH
|
June 25, 2017
The Dietary Approaches to Stop Hypertension (DASH) diet-Promise Unmet
Michael J Bloch
Journal of Clinical Hypertension (Greenwich, Conn.)
|
February 3, 2007
British hypertension society recommends that beta-blockers are no longer indicated as initial treatment of hypertension: has the pendulum swung too far?
Michael J Bloch
Journal of the American Society of Hypertension : JASH
|
April 13, 2016
GIVING PHARMACISTS ABILITY TO PRESCRIBE ANTIHYPERTENSION MEDICATIONS CAN IMPROVE BLOOD PRESSURE CONTROL RATES
Michael J Bloch
Journal of Clinical Hypertension (Greenwich, Conn.)
|
January 12, 2007
Do angiotensin receptor antagonists decrease hsCRP independent of blood pressure - and does it matter?
Michael J Bloch
Journal of the American Society of Hypertension : JASH
|
July 14, 2016
Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension
Michael J Bloch
Journal of Clinical Hypertension (Greenwich, Conn.)
|
October 18, 2005
Lower levels of microalbuminuria are associated with an increased risk of coronary heart disease and death in hypertensive subjects
Michael J Bloch, Jan Basile
Page
of 12
Search research articles
Search
Showing results (1-10 of 115) with videos related to
Sort By:
Page
of 12
Journal of Clinical Hypertension (Greenwich, Conn.)
|
July 30, 2013
What does ALLHAT tell us about dyslipidemia from the hypertension specialist perspective?
Michael J Bloch
Journal of the American College of Cardiology
|
July 18, 2020
Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?
Michael J Bloch
Journal of the American Society of Hypertension : JASH
|
June 10, 2016
Spironolactone is the Most Effective "add-on" Medication For Resistant Hypertension
Michael J Bloch
Journal of the American Society of Hypertension : JASH
|
September 24, 2016
Worldwide prevalence of hypertension exceeds 1.3 billion
Michael J Bloch
Journal of the American Society of Hypertension : JASH
|
June 25, 2017
The Dietary Approaches to Stop Hypertension (DASH) diet-Promise Unmet
Michael J Bloch
Journal of Clinical Hypertension (Greenwich, Conn.)
|
February 3, 2007
British hypertension society recommends that beta-blockers are no longer indicated as initial treatment of hypertension: has the pendulum swung too far?
Michael J Bloch
Journal of the American Society of Hypertension : JASH
|
April 13, 2016
GIVING PHARMACISTS ABILITY TO PRESCRIBE ANTIHYPERTENSION MEDICATIONS CAN IMPROVE BLOOD PRESSURE CONTROL RATES
Michael J Bloch
Journal of Clinical Hypertension (Greenwich, Conn.)
|
January 12, 2007
Do angiotensin receptor antagonists decrease hsCRP independent of blood pressure - and does it matter?
Michael J Bloch
Journal of the American Society of Hypertension : JASH
|
July 14, 2016
Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension
Michael J Bloch
Journal of Clinical Hypertension (Greenwich, Conn.)
|
October 18, 2005
Lower levels of microalbuminuria are associated with an increased risk of coronary heart disease and death in hypertensive subjects
Michael J Bloch, Jan Basile
Page
of 12